BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26496320)

  • 1. Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis.
    Yang L; Du S
    Medicine (Baltimore); 2015 Oct; 94(42):e1822. PubMed ID: 26496320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
    Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
    Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis.
    Wang Y; Tang Z; Meng R; He L
    Ann Palliat Med; 2021 Nov; 10(11):11950-11959. PubMed ID: 34872319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
    Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
    Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
    Peddi P; Lopez-Olivo MA; Pratt GF; Suarez-Almazor ME
    Cancer Treat Rev; 2013 Feb; 39(1):97-104. PubMed ID: 22898302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
    Major P
    Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
    Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
    Coleman RE
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S25-31. PubMed ID: 12562048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
    He M; Fan W; Zhang X
    J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.